![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
P Nambi, HL Wu, M Pullen, N Aiyar, H Bryan and J Elliott
Department of Pharmacology, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania 19406-0939.
125I-Endothelin (ET)-1 and 125I-ET-3 displayed specific, saturable, and high affinity binding to membranes prepared from rat kidney cortex. Saturation binding experiments using 125I-ET-1 and 125I-ET-3 revealed that 125I-ET-3 binding sites were 40-50% less abundant than 125I-ET-1 binding sites. The dissociation constants (Kd) and maximum binding (Bmax) for 125I-ET-1 and 125I-ET-3 with these membranes were 218 +/- 23 pM and 275 +/- 20 fmol/mg of protein and 207 +/- 19 pM and 113 +/- 17 fmol/mg of protein, respectively. In the presence of 10 nM sarafotoxin 6c, a selective agonist for ETb receptors, 125I-ET-1 binding was decreased by 45-50% and 125I-ET-3 binding was totally abolished, suggesting that approximately 40-50% of kidney cortex ET receptors are of the ETB subtype and that 125I-ET-1 binds to both ETA and ETB receptors with the same high affinity, whereas 125I-ET-3 binds to only ETB receptors with high affinity. In addition, in the presence of BQ123 [cyclo(D-Trp,D-Asp,L-Pro,D-Val,L-Leu)], a selective antagonist for ETA receptors, 125I-ET-1 binding was decreased by 50%, whereas 125I-ET-3 binding was unaffected. Our results strongly suggest that rat kidney cortex contains ETA and ETB receptors in a 50:50 ratio and that sarafotoxin 6c and BQ123 are valuable tools in identifying the subtypes of ET receptors in various tissues.
This article has been cited by other articles:
|
|
 |
|
  T. A. Taylor, C. E. Gariepy, D. M. Pollock, and J. S. Pollock Unique endothelin receptor binding in kidneys of ETB receptor deficient rats Am J Physiol Regulatory Integrative Comp Physiol, March 1, 2003; 284(3): R674 - R681. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R Anand, D Harry, S Holt, P Milner, M Dashwood, D Goodier, M Jarmulowicz, and K Moore Endothelin is an important determinant of renal function in a rat model of acute liver and renal failure Gut, January 1, 2002; 50(1): 111 - 117. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Itoh, M. Takaoka, A. Shibata, M. Ohkita, and Y. Matsumura Preventive Effect of Lactacystin, a Selective Proteasome Inhibitor, on Ischemic Acute Renal Failure in Rats J. Pharmacol. Exp. Ther., August 1, 2001; 298(2): 501 - 507. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Yamashita, M. Itoh, T. Kuro, Y. Kobayashi, M. Ogata, M. Takaoka, and Y. Matsumura Pre- or Post-Ischemic Treatment with a Novel Na+/Ca2+ Exchange Inhibitor, KB-R7943, Shows Renal Protective Effects in Rats with Ischemic Acute Renal Failure J. Pharmacol. Exp. Ther., April 13, 2001; 296(2): 412 - 419. [Abstract] [Full Text]
|
|
|
|
 |
|
 T.-J. Hsieh, S.-R. Lin, Y.-J. Lee, S.-J. Shin, Y.-H. Lai, C.-H. Hsu, and J.-H. Tsai Increased renal medullary endothelin-1 synthesis in prehypertensive DOCA- and salt-treated rats Am J Physiol Renal Physiol, July 1, 2000; 279(1): F112 - F121. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Nambi, M. Pullen, J. Kincaid, P. Nuthulaganti, N. Aiyar, D. P. Brooks, M. Gellai, and C. Kumar Identification and Characterization of a Novel Endothelin Receptor That Binds Both ETA- and ETB-Selective Ligands Mol. Pharmacol., October 1, 1997; 52(4): 582 - 589. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
